Acorda Therapeutics

Business model

Commercial-stage biopharmaceutical selling neurology treatments including Ampyra/Fampyra for MS and Inbrija for Parkinson's.

In brief

A commercial-stage neurology company with actual approved, revenue-generating drugs on the market for nearly three decades, including a treatment for multiple sclerosis and one for Parkinson's disease. Years of declining sales as key drugs lost patent exclusivity, combined with a…

See the What Happened tab for the full account.